We ended the previous week with the FDA approval for Lecanemab treating Alzheimer's. We'll track and share the future events as they unfold in the Alzheimer's space. But as we turn our attention to the upcoming week we kick it off with the JP Morgan conference starting 1/9. We expect to see lots of updates from companies including M&A activity, revenue guidance, and other big updates. We also have a lot of catalysts coming these weeks. See below for a table full of major events you should keep an eye on. Also we're having a 60% OFF sale on both premium annual options in honor of the JPM conference. Take advantage of this offer before it's gone. Learn more here.
Weekly Watchlist Highlights:
The 41st Annual J.P. Morgan Health Care Conference is taking place in San Francisco, AC from January 9-12, 2023. Many of the smid-cap biopharma companies in the BPIQ.com database will be presenting at this conference, at which time companies may update timing of upcoming trials or readouts, or rarely, but sometimes give updated data at the conference. See our forum post HERE for additional info on these companies, after subscribing. Learn more here.
SGENS's asset Tucatinib has a PDUFA target action date of January 19, 2023. Tucatinib could be approved for metastatic colorectal cancer and SGEN is in partnership with MRK for this asset. The NDA for Tucatinib was accepted in September 2022. Currently several other smid-cap biopharmas are in Phase 2 or 3 trials for mCRC as well.
Cidara has an Adcom meeting on 1/24/23 for their drug Rezafungin for the treatment of candidemia and invasive candidiasis. The NDA submission for rezafungin was supported by positive clinical data from the global ReSTORE Phase 3 and STRIVE Phase 2 clinical trials. CDTX is a BPIQ Big Mover™ stock to watch so keep it on your radar.
コメント